Faslodex 500mg multiple dose tolerability study in BC patients
Study identifier:D6995C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, multicentre Phase I clinical study to assess the tolerability of fulvestrant 500 mg in postmenopausal women with hormone receptor positive advanced or recurrent breast cancer
Medical condition
Advanced breast cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
Fulvestrant
Sex
Female
Actual Enrollment
20
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Apr 2004
Primary Completion Date: 01 Apr 2006
Study Completion Date: 01 Jun 2010
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Breast Cancer Established Brands Team Medical Science Director
AstraZeneca
